Dr David S. Perlin, PhD is a highly- accomplished administrator and medical researcher. He serves as the inaugural Chief Scientific Officer and Senior Vice President for the Hackensack Meridian Health Center for Discovery and Innovation, developed as a major translational research enterprise to rapidly develop innovation in science to improve outcomes for patients with cancer and infectious diseases. He was previously Executive Director of the Rutgers New Jersey Medical School’s Public Health Research Institute (PHRI), a 77-year-old specialized center for global infectious diseases. He was also Director of the Rutgers Regional Biocontainment Laboratory (RBL), one of thirteen NIH-designated national centers for pathogen research, and a Professor of Microbiology, Biochemistry and Molecular Genetics. Dr Perlin help establish PHRI as a leading translational research organization specializing in infectious diseases. As Executive Director over the past decade, PHRI attracted >$200 million in research funds and produced more than $80 million in licensing income from >200 patents.
Dr. Perlin’s research emphasizes studies to diagnose and overcome drug-resistant fungal and bacterial infections in high-risk patients, and he is widely regarded as a global leader in antifungal drug resistance and fungal molecular diagnostics. He has published more than 250 papers and book chapters and has co-authored two books. His laboratory is supported by multiple grants from the NIH, DoD, Pharma and biopharma sectors. The NIH has continuously funded him for 30 years, and he currently leads an NIH-designated National Center of Excellence in Translational Research to discover novel antibiotics and against drug-resistant bacterial infections. Dr Perlin’s recent awards include being named a Fellow of the New York Academy of Sciences and a Fellow of the American Academy of Microbiology.